VNDA · XBRL financial data

Vanda Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VNDA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	248,168	268,682	254,382	192,640	198,772	216,105
Revenue from contracts with customers	248,168	268,682	254,382	192,640	198,772	216,105
Research and development	55,577	75,363	85,770	76,823	74,431	109,271
Selling, general and administrative	140,510	124,047	136,485	112,883	146,414	237,951
Operating income (loss)	27,239	42,165	6,329	(13,952)	(40,660)	(151,168)
Income tax expense (benefit)	8,318	9,212	5,025	3,830	(4,021)	81,827
Net income (loss)	23,337	33,152	6,275	2,509	(18,900)	(220,474)
Earnings per share, basic USD per share	0.43	0.60	0.11	0.04	(0.33)	(3.74)
Earnings per share, diluted USD per share	0.42	0.58	0.11	0.04	(0.33)	(3.74)
Weighted average shares, basic thousands of shares	54,428	55,548	56,462	57,381	58,149	58,930
Weighted average shares, diluted thousands of shares	55,191	56,922	56,983	57,558	58,149	58,930

Fiscal years (VNDA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	61,031	52,071	135,029	135,821	102,316	84,851
Marketable securities	306,709	380,742	—	—	—	—
Accounts receivable	30,036	32,467	33,512	34,155	47,101	54,578
Inventory	1,280	1,025	1,194	1,357	1,726	1,852
Prepaid and other current assets	10,089	11,996	17,727	9,170	15,420	26,985
Total current assets	409,145	478,301	519,292	432,946	438,890	347,262
Property and equipment, net	4,136	3,113	2,573	2,037	2,132	2,248
Right-of-use asset	10,459	9,272	8,400	7,103	5,602	3,923
Total assets	533,456	593,792	634,247	648,440	656,204	488,948
Total current liabilities	65,936	74,419	91,436	87,697	99,981	145,162
Lease liability, non-current	11,497	10,055	8,813	7,006	4,944	2,991
Total liabilities	80,190	88,864	107,049	103,530	117,658	161,762
Accumulated deficit	(197,328)	(164,176)	(157,901)	(155,392)	(174,292)	(394,766)
Total stockholders' equity	453,266	504,928	527,198	544,910	538,546	327,186
Total liabilities and equity	533,456	593,792	634,247	648,440	656,204	488,948
Common shares outstanding (cover page) thousands of shares	54,883	55,907	56,785	57,537	58,316	59,108

Fiscal years (VNDA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	23,337	33,152	6,275	2,509	(18,900)	(220,474)
Stock-based compensation	13,360	15,374	16,279	14,040	12,432	9,474
Net cash from operating activities	51,775	64,214	31,984	12,801	(15,757)	(109,442)
Purchases of property and equipment	1,795	552	679	383	490	998
Net cash from investing activities	(41,499)	(76,696)	49,925	(12,056)	(17,430)	94,860
Proceeds from issuing common stock	0	—	—	—	—	—
Net cash from financing activities	5,634	3,550	734	0	(155)	(2,906)
Net change in cash	15,963	(9,023)	82,908	792	(33,505)	(17,465)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Vanda Pharmaceuticals	61,933	69,815	(28,435)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Tonix Pharmaceuticals Holding	176,232	13,544	(42,243)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Abeona Therapeutics	56,229	11,380	(17,496)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Atea Pharmaceuticals	76,548	not reported	(37,084)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Ocugen	100,051	1,488	(12,198)*	339.1M	8.2 quarters	Q2 FY26 10-QJun 30, 2026
Verastem	136,353	40,078	(43,909)*	90.6M	3.1 quarters	Q2 FY26 10-QJun 30, 2026
Corvus Pharmaceuticals	18,905	not reported	(15,398)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	165,700	1,600	(51,500)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Standard Biotools	267,487	19,385	(6,161)*	394.8M	21.6 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.